Pharming Group Dividend 2025

Pharming Group N.V., is a company with a worldwide presence dedicated to the biopharmaceutical sector, especially in the research and creation of treatments for rare or uncommon, debilitating diseases with a high mortality rate.

It is headquartered in Leiden, the Netherlands, and New Jersey, USA, but serves approximately 30 markets in Europe, the Middle East, North America, Africa and Asia, with more than 300 employees.

The group focuses on commercializing therapies based on protein replacement, as well as precision medicines, having partners at any level or stakeholder, from patients, healthcare professionals, employees, small laboratories, suppliers, external shareholders, among others.

Among its most representative drugs are RUCONEST® (conestat alfa) and JOENJA® (leniolisib), both approved by the EMA (European Medicines Agency) for marketing in Europe, by the FDA (Food and Drug Administration) for the United States and by the MHRA (Medicines and Healthcare products Regulatory Agency) for the United Kingdom.

Their technological platform is mainly based on the use of rhC1INH, although they are working on the development or acquisition of other methods to be used in their processes, in addition they also have in their platform as part of their services the monitoring and opportunity to report any adverse event, trying to comply with the global health care requirements and to update their products.

In addition, they are developing programs for the treatment of ADPS (sticky platelet syndrome), which is an abnormal, genetic and progressive immunodeficiency, as well as the research, creation and commercialization of OTL-105, a gene therapy that acts with stem cells to treat hereditary angioedema (HAE), which is being developed in collaboration with Orchard Therapeutics.